文献速递睡眠呼吸障碍

Solriamfetol治疗OSA日间过度嗜睡的安慰剂对照随机撤药研究

Solriamfetol for the Treatment of Excessive Sleepiness in OSA: A Placebo-Controlled Randomized Withdrawal Study.
PubMed 文献 · Chest · 2018-11-22

本III期随机撤药试验评估solriamfetol(JZP-110)对成人OSA日间过度嗜睡的疗效。经2周滴定和2周稳定剂量后,符合改善标准的参与者随机接受安慰剂或solriamfetol治疗2周。结果显示solriamfetol维持了清醒度与嗜睡改善,而安慰剂组恶化,组间差异显著。

要点

  • Solriamfetol在6周内维持了OSA患者日间嗜睡的改善效果。
  • 撤药至安慰剂后MWT和ESS显著恶化,组间差异有临床意义。
  • 常见不良事件包括头痛、口干、恶心、头晕和失眠。

核心结论

  • Solriamfetol在6周内维持了对OSA患者日间过度嗜睡的疗效和安全性。

研究设计与样本

  • III期随机撤药试验,经2周滴定(n=174)和2周稳定剂量(n=148)后,符合PGI-C改善且MWT和ESS数值改善的参与者随机接受安慰剂(n=62)或solriamfetol(n=62)治疗2周。

主要发现

  • 改良意向治疗人群(n=122)中,MWT平均睡眠潜伏期和ESS评分从基线至第4周改善(分别从12.3-13.1至29.0-31.7分钟和从15.3-16.0至5.9-6.4)。
  • 从第4周到第6周,solriamfetol组维持改善(MWT最小二乘均值[SE]变化-1.0[1.4]分钟,ESS -0.1[0.7]),安慰剂组恶化(MWT -12.1[1.3]分钟,ESS 4.5[0.7])。
  • 组间最小二乘均值差异:MWT 11.2分钟(95%CI 7.8-14.6),ESS -4.6(95%CI -6.4至-2.8)。
  • 第4至6周solriamfetol组PGI-C报告恶化的参与者比例低于安慰剂组(20% vs 50%;P = .0005)。

临床怎么用

  • Solriamfetol可用于OSA患者日间过度嗜睡的治疗,需注意头痛、口干、恶心、头晕和失眠等不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Excessive sleepiness (ES) is a common symptom of OSA, which often persists despite primary OSA therapy. This phase III randomized withdrawal trial evaluated solriamfetol (JZP-110) for the treatment of ES in adults with OSA. METHODS: After 2 weeks of clinical titration (n = 174) and 2 weeks of stable dose administration (n = 148), participants who reported improvement on the Patient Global Impression of Change (PGI-C) and had numerical improvements on the Maintenance of Wakefulness Test (MWT) and Epworth Sleepiness Scale (ESS) were randomly assigned to placebo (n = 62) or solriamfetol (n = 62) for 2 additional weeks. Coprimary end points were change from weeks 4 to 6 in MWT and ESS. RESULTS: In the modified intention-to-treat population (n = 122), MWT mean sleep latencies and ESS scores improved from baseline to week 4 (from 12.3-13.1 to 29.0-31.7 minutes and from 15.3-16.0 to 5.9-6.4, respectively). From weeks 4 to 6, participants treated with solriamfetol maintained improvements (least squares [LS] mean [SE] changes of -1.0 [1.4] minutes on MWT and -0.1 [0.7] on ESS), whereas participants treated with placebo worsened (LS mean [SE] change of -12.1 [1.3] minutes on MWT and 4.5 [0.7] on ESS); LS mean differences between treatments were 11.2 minutes (95% CI, 7.8-14.6) and -4.6 (95% CI, -6.4 to -2.8) on MWT and ESS, respectively. Fewer participants treated with solriamfetol reported worsening on the PGI-C from weeks 4 to 6 (20% vs 50%; P = .0005). Common adverse events included headache, dry mouth, nausea, dizziness, and insomnia. CONCLUSIONS: This study demonstrated maintenance of solriamfetol efficacy and safety over 6 weeks. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT02348619; URL: www.clinicaltrials.gov; EudraCT No.: 2014-005515-16.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Strollo PJ, Hedner J, Collop N, et al. Solriamfetol for the Treatment of Excessive Sleepiness in OSA: A Placebo-Controlled Randomized Withdrawal Study. Chest. 2018. PMID: 30471270. doi:10.1016/j.chest.2018.11.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。